Calamos Advisors LLC Acquires Shares of 66,431 Inotiv, Inc. (NASDAQ:NOTV)

Calamos Advisors LLC acquired a new stake in shares of Inotiv, Inc. (NASDAQ:NOTV) during the 4th quarter, according to its most recent disclosure with the SEC. The fund acquired 66,431 shares of the company’s stock, valued at approximately $275,000.

Several other large investors have also bought and sold shares of the company. Vantage Point Financial LLC bought a new stake in Inotiv during the 4th quarter valued at approximately $1,393,000. KPP Advisory Services LLC boosted its position in Inotiv by 15.8% during the 4th quarter. KPP Advisory Services LLC now owns 275,267 shares of the company’s stock valued at $1,140,000 after acquiring an additional 37,549 shares in the last quarter. Thurston Springer Miller Herd & Titak Inc. boosted its position in Inotiv by 612.5% during the 4th quarter. Thurston Springer Miller Herd & Titak Inc. now owns 127,257 shares of the company’s stock valued at $527,000 after acquiring an additional 109,397 shares in the last quarter. Geode Capital Management LLC boosted its position in Inotiv by 7.7% during the 3rd quarter. Geode Capital Management LLC now owns 250,895 shares of the company’s stock valued at $427,000 after acquiring an additional 18,039 shares in the last quarter. Finally, Renaissance Technologies LLC boosted its position in Inotiv by 29.9% during the 2nd quarter. Renaissance Technologies LLC now owns 164,164 shares of the company’s stock valued at $273,000 after acquiring an additional 37,800 shares in the last quarter. 18.17% of the stock is owned by institutional investors.

Insider Transactions at Inotiv

In other news, Director David Landman acquired 23,529 shares of the firm’s stock in a transaction that occurred on Thursday, December 19th. The stock was bought at an average cost of $4.25 per share, for a total transaction of $99,998.25. Following the acquisition, the director now directly owns 176,851 shares in the company, valued at approximately $751,616.75. The trade was a 15.35 % increase in their ownership of the stock. The acquisition was disclosed in a filing with the SEC, which can be accessed through this link. Also, CEO Robert Jr. Leasure sold 22,700 shares of the business’s stock in a transaction that occurred on Friday, January 31st. The stock was sold at an average price of $4.15, for a total transaction of $94,205.00. Following the completion of the transaction, the chief executive officer now owns 1,030,209 shares of the company’s stock, valued at approximately $4,275,367.35. The trade was a 2.16 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last ninety days, insiders have purchased 71,029 shares of company stock valued at $314,248 and have sold 26,872 shares valued at $112,854. Insiders own 7.80% of the company’s stock.

Inotiv Stock Performance

Shares of NOTV opened at $4.18 on Thursday. The company has a quick ratio of 1.22, a current ratio of 1.37 and a debt-to-equity ratio of 2.29. The business’s 50 day moving average price is $4.43 and its 200-day moving average price is $2.80. Inotiv, Inc. has a 52 week low of $1.23 and a 52 week high of $11.42. The stock has a market cap of $108.72 million, a P/E ratio of -1.00 and a beta of 3.58.

Inotiv (NASDAQ:NOTV) last issued its quarterly earnings results on Wednesday, February 5th. The company reported ($0.42) EPS for the quarter, missing analysts’ consensus estimates of ($0.32) by ($0.10). Inotiv had a negative return on equity of 15.86% and a negative net margin of 22.10%. Equities research analysts anticipate that Inotiv, Inc. will post -0.75 earnings per share for the current fiscal year.

About Inotiv

Inotiv, Inc provides nonclinical and analytical drug discovery and development services to the pharmaceutical and medical device industries. It operates through two segment: Discovery and Safety Assessment (DSA), and Research Models and Services (RMS). The DMS segment manufactured scientific instruments for life sciences research and the related software for use by pharmaceutical companies, universities, government research centers, and medical research institutions under the Company's BASi product line.